Drug Profile


Alternative Names: BU 4344V; Kistamicin A; Kistamicin B

Latest Information Update: 18 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DuPont
  • Developer Bristol-Myers Squibb
  • Class Antibacterials; Antivirals; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gram-positive infections; Influenza virus infections

Most Recent Events

  • 20 Aug 1999 No-Development-Reported for Gram-positive infections in Japan (Unknown route)
  • 20 Aug 1999 No-Development-Reported for Influenza virus infections in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top